January 2024

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additional triple

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: